Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Alnylam Pharmaceuticals Inc ALNY
$288.51
▲ +0.53%
(+$1.53)
Index member:
NASDAQ-100
Open
$288.73
Prev Close
$286.98
Day Range
$285.26 – $291.97
52W Range
$266.18 – $495.55
Market Cap
$38.92B
P/E (TTM)
66.44
Beta
0.26
EPS (TTM)
$4.18
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-05-28 |
| Shares Out. | 133,430,000 |
| Website | alnylam.com/ ↗ |
| Phone | 13026587581 |
Alnylam Pharmaceuticals Inc is a publicly traded company under the ticker symbol ALNY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
36 analysts (2026-05-01)
📰 Latest News for ALNY
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy?
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10
Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients